载吡柔比星微球经导管肝动脉化疗栓塞术联合阿帕替尼在原发性肝癌患者介入治疗中的应用价值  

Application Value of Transcatheter Arterial Chemoembolization with Pirarubicin-loaded Microspheres Combined with Apatinib Therapy in the Interventional Treatment of Patients with Primary Liver Cancer

作　　者：何耀强[1] 陈焕伟[2] 杨少苏 HE Yao-qiang;CHEN Huan-wei;YANG Shao-su(Department of Imaging1,Foshan First People's Hospital,Foshan 528000,Guangdong,China;Department of Liver Surgery,Foshan First People's Hospital,Foshan 528000,Guangdong,China)

机构地区：[1]佛山市第一人民医院影像科,广东佛山528000 [2]佛山市第一人民医院肝外科,广东佛山528000

出　　处：《医学信息》2024年第1期125-129,共5页Journal of Medical Information

摘　　要：目的探究载吡柔比星微球经导管肝动脉化疗栓塞术联合阿帕替尼治疗原发性肝癌的效果。方法选取2020年1月-2021年6月于佛山市第一人民医院进行原发性肝癌介入治疗的185例患者作为研究对象,根据治疗方法不同分为观察组(93例)和对照组(92例)。观察组采用载吡柔比星微球TACE联合阿帕替尼治疗,而对照组采用吡柔比星+碘油TACE联合阿帕替尼治疗。比较两组无进展生存期(PFS)、总生存期、临床总有效率、甲胎蛋白(AFP)水平及不良反应情况。结果观察组PFS长于对照组(P<0.05);观察组随访12个月生存率高于对照组,差异有统计学意义(P<0.05),但两组随访6、18个月生存率比较,差异无统计学意义(P>0.05);观察组临床有效率、疾病控制率高于对照组(P<0.05);两组治疗后AFP水平低于治疗前,且观察组低于对照组(P<0.05);观察组恶心呕吐发生低于对照组(P<0.05),但两组疼痛和发热发生率比较,差异无统计学意义(P>0.05)。结论与传统TACE相比,载药微球搭载吡柔比星TACE联合阿帕替尼治疗原发性肝癌的效果更好,可延长患者原发性肝癌,提高患者生存率,同时胃肠道反应更轻。Objective To investigate the effect of transcatheter arterial chemoembolization with pirarubicin-loaded microspheres combined with apatinib orally in the treatment of patients with primary liver cancer.Methods A total of 185 patients who underwent interventional therapy for primary liver cancer in Foshan First People's Hospital from January 2020 to June 2021 were selected as the research objects.According to different treatment methods,they were divided into observation group(93 patients)and control group(92 patients).The observation group was treated with pirarubicin-loaded microsphere TACE combined with apatinib,while the control group was treated with pirarubicin+lipiodol TACE combined with apatinib.The progression-free survival(PFS),overall survival,clinical total effective rate,alpha-fetoprotein(AFP)level and adverse reactions were compared between the two groups.Results The PFS of the observation group was longer than that of the control group(P<0.05).The survival rate of the observation group was higher than that of the control group after 12 months of follow-up,and the differences were statistically significant(P<0.05),but there was no significant difference in the survival rate between the two groups after 6 and 18 months of follow-up(P>0.05).The clinical effective rate and disease control rate of the observation group were higher than those of the control group(P<0.05).After treatment,the AFP level of the two groups was lower than that before treatment,and that of the observation group was lower than that of the control group(P<0.05).The incidence of nausea and vomiting in the observation group was lower than that in the control group(P<0.05),but there was no significant difference in the incidence of pain and fever between the two groups(P>0.05).Conclusion Compared with traditional TACE,transcatheter arterial chemoembolization with pirarubicin-loaded microspheres combined with apatinib is more effective in the treatment of PLC,which can prolong the PFS of patients,improve the survival rate of patients,

关 键 词：载吡柔比星微球 经导管肝动脉化疗栓塞术 阿帕替尼 原发性肝癌 

分 类 号：R735.7[医药卫生—肿瘤]